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Abstract
The aim of the present work is to compare drug survival and
safety of infliximab, etanercept, and adalimumab (tumor necrosis
factor [TNF] antagonists) in spondylarthritis (SpA) with those of
rheumatoid arthritis (RA). To this purpose, we analysed the data
in BIOBADASER (2000–2005), a drug registry launched in
2000 for long-term follow-up of the safety of these biologics in
rheumatic diseases. The rates of drug discontinuation and
adverse events (AEs) in SpA (n = 1,524) were estimated and
compared with those of RA (n  = 4,006). Cox regression
analyses were used to adjust for independent factors. Total
exposure to TNF antagonists for SpA was 2,430 patient-years
and 7,865 for RA. Drug survival in SpA was significantly greater
t h a n  i n  R A  a t  1 ,  2 ,  a n d  3  y e a r s .  T h e  h a z a r d  r a t i o  ( H R )  f o r
discontinuation in SpA compared with RA was 0.66 (95%
confidence interval [CI], 0.57–0.76) after adjustment for age,
gender, and use of infliximab. The difference remained after
controlling for the individual medication and its place in the
sequence of treatment. There were fewer SpA patients with AEs
(17%) than RA patients (26%; p < 0.001). The HR for AEs in
SpA was 0.80 (95% CI, 0.70–0.91) compared with RA after
adjustment for age, disease duration, and use of infliximab. In
conclusion, due in part to a better safety profile, survival of TNF
antagonists in SpA is better than in RA. TNF antagonists are at
present a safe and effective therapeutic option for long-term
treatment of patients with SpA failing to respond to traditional
drugs. Because chronic therapy is necessary, continual review
of this issue is necessary.
Introduction
The term spondylarthritis (SpA) refers to a group of conditions
with inflammation at the entheses, axial skeleton, peripheral
joints, and non-articular structures [1-3]. It includes ankylosing
spondylitis (AS), reactive arthritis, undifferentiated SpA, juve-
nile spondylitis, and the arthritis associated with psoriasis or
inflammatory bowel diseases. These conditions occur in
approximately 1% of the general population [3]. Because of
overlapping clinical features, diagnosis of any single one from
among the several within the group is sometimes difficult. Nev-
ertheless, treatment does not differ very much among the dif-
ferent conditions. Non-steroidal anti-inflammatory drugs
(NSAIDs) have a role in symptom modification and disease
control in patients with AS [4,5] as do methotrexate and sul-
fasalazine with psoriatic arthritis (PsA) and AS [6-17]. In both
conditions, these drugs have demonstrated some benefit in
peripheral arthritis. In axial disease, evidence is lacking.
Recently, tumor necrosis factor (TNF) inhibitors have been
found to be safe and effective in the short-term management
of AS, PsA, enteropathic arthritis, and juvenile SpA in patients
failing to respond to traditional therapies [17-34]. Unlike in
rheumatoid arthritis (RA), however, their long-term efficacy and
safety in such conditions are largely unknown.
In February 2000, the Spanish Society of Rheumatology
(SER) launched a drug registry (BIOBADASER) of patients
with any rheumatic condition treated with biologic disease
modifiers. In the past 5 years, more than 5,000 patients from
100 centres have been included in the registry and followed
up with [35]. Although the emphasis of BIOBADASER is in
AE = adverse event; AS = ankylosing spondylitis; BASDAI = bath ankylosing spondylitis disease activity index; CI = confidence interval; DMARD = 
disease-modifying antirheumatic drug; HR = hazard ratio; NSAID = non-steroidal anti-inflammatory drug; PsA = psoriatic arthritis; RA = rheumatoid 
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drug safety, information on drug discontinuation for any cause
is gathered as well. For prescription of any biological disease
modifier in a context of universal health coverage in Spain, the
physician commits himself to assess effectiveness and safety
regularly and discontinue medication when appropriate to
meet our current guidelines. Thus, drug survival in this particu-
lar clinical setting may be considered a surrogate for effective-
ness. Consistency of the data in our registry, which have been
externally assessed as described in Materials and methods,
and comparison of drug survival in different conditions offer a
unique opportunity for the detection of relevant differences in
safety and effectiveness. In the present work, we describe the
differences in the survival and safety of TNF antagonist in SpA
compared with the well-known profile in RA.
Materials and methods
A description of BIOBADASER has been published else-
where [28], and its protocol and periodical reports are availa-
ble on its Web page [36]. In brief, BIOBADASER is a drug
registry established in February 2000 for active long-term fol-
low-up of rheumatic patients being treated with biological
response modifiers. Patients treated with infliximab before the
start of the registry were also included if complete history of
treatment and information on adverse events (AEs) were avail-
able. The registry, which is supported by the SER and funded
in part by the Spanish Agency for Medicines and Health-Serv-
ice Products (Agencia Española de Medicamentos y Produc-
tos Sanitarios), notes relevant AEs (RAEs) occurring during
treatment. All hospital and community-based Rheumatology
Units in Spain were invited to participate in setting up the
project. Participation is voluntary, covering approximately 60%
of the patients treated with these therapies for rheumatic dis-
eases in Spain. The large number of participating units (100)
ensures a true mix of hospital and community-based practices.
A random code is assigned to every patient entered. This code
will be kept throughout the follow-up, until death, or until the
study closure date. The registry protocol and methods were
approved by the Spanish Medicines Agency (Ministerio de
Sanidad y Consumo), and the information regarding patients
was gathered in the registry and handled according to current
official regulations on data protection.
Data collected systematically include gender, date of birth,
diagnosis, date of diagnosis, treatment type, date of start, and
date of discontinuation. Should a patient discontinue treat-
ment, the main reason for end is also recorded (for example,
inefficacy, AE, or other causes). When a patient has an RAE,
additional data are registered; these data include the date of
occurrence, type, and classification of event according to the
World Health Organization Adverse Reaction Dictionary.
Completeness and agreement of data with patient charts were
assessed  in situ by audits of 15% of patients' records
between December 2003 and March 2004 and by telephone
of 10% of patients' records between December 2004 and
January 2005. Non-communication of the TNF antagonist dis-
continuation was detected in 6% of cases and non-communi-
cation of RAE in 16%; non-communication of either
discontinuation or RAE was present in 18% of the sample. All
errors were corrected accordingly and yielded an expected
error rate, in the whole BIOBADASER sample, of approxi-
mately 11%.
Table 1
Characteristics of patients with spondylarthritis and rheumatoid arthritis in BIOBADASER and medications used by diagnosis
Total treatments with biologics, n (percentage) 
by diagnosis
n (percentage) by diagnosis in 
BIOBADASER
Age* n (percentage), 
women
Disease duration* Infliximab Etanercept Adalimumab
Rheumatoid arthritis 4,006 (68.5) 54 ± 13 3,166 (79.0) 10 ± 7 2,789 (60.6) 1,170 (25.4) 577 (12.5)
All spondylarthritis 1,524 (26.0) 45 ± 12† 537 (35.2)† 10 ± 8 1,180 (70.7) 472 (28.3) 15 (0.9)†
Ankylosing spondylitis 657 (11.2) 45 ± 12 152 (23.1) 12 ± 8 570 (80.5) 136 (19.2) 2 (0.3)
Psoriatic arthritis 570 (9.7) 47 ± 12 270 (47.4) 9 ± 7 347 (54.5) 281 (44.1) 9 (1.4)
Undifferentiated 
spondylarthritis
187 (3.2) 43 ± 12 70 (37.4) 8 ± 7 162 (79.0) 41 (20.0) 2 (1.0)
Crohn's disease arthritis 68 (1.2) 38 ± 13 32 (47.1) 7 ± 8 68 (94.4) 2 (2.8) 1 (1.4)
Juvenile spondylarthritis 19 (0.3) 30 ± 12 7 (36.8) 17 ± 14 17 (89.5) 2 (10.5) -
Reactive arthritis 12 (0.2) 49 ± 9 2 (16.7) 8 ± 7 10 (83.3) 2 (16.7) -
Chronic seronegative 
oligoarthritis
11 (0.2) 35 ± 9 4 (36.4) 4 ± 3 6 (40.0) 8 (53.3) 1 (6.7)
*In years, mean ± standard deviation
†p < 0.001 of the difference between rheumatoid arthritis and spondylarthritis as a group.Available online http://arthritis-research.com/content/8/3/R72
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Guidelines for the use of TNF antagonists in patients with SpA
were available through the SER at the beginning of 2005. Cri-
teria for eligibility of patients with axial disease comprise failure
to respond to two NSAIDs, bath AS disease activity index
(BASDAI) greater than 4, and additional clinical criteria. For
peripheral joint disease, TNF antagonists are recommended
for patients who failed to respond to two NSAIDs and sul-
phasalazine and who have a self-assessment of the disease in
a visual analog scale greater than 4 cm and an elevation of
acute-phase reactants. These guidelines do not contain rec-
ommendations for discontinuation. Prior to this date, biologics
were used based on the judgement of the rheumatologist,
most often following the criteria settled previously for their
application as compassionate medication. These criteria were
more stringent and include a BASDAI greater than 6.5 units
for spinal disease, more than five inflamed joints, and radio-
graphic erosive changes for peripheral arthritis in any case in
which a patient failed to respond to two NSAIDs and two dis-
ease-modifying antirheumatic drugs (DMARDs). In Spain, inf-
liximab was available for clinical use in August 1999,
etanercept in April 2003, and adalimumab in February 2004.
For AS, infliximab was approved in May 2003 and etanercept
in January 2004. For PsA, infliximab was available in Septem-
ber 2004 and etanercept in December 2002. For the other
types of SpA, biologics are used as compassionate medica-
tion. All three biologics (infliximab, etanercept, and adalimu-
mab) are provided free of charge to patients and without
restriction at the hospital level by the National Health Service.
Data in the present study correspond to those gathered from
the start of the registry to February 2005. Data that are incom-
plete are censored at the time the last reliable information was
recorded. The censoring was done to avoid having long drug
survival that reflected under-reporting rather than true drug
retention.
Statistical methods
The cumulative rate of discontinuation was calculated using
the actuarial method, accounting for multiple failures per
patient and for the calendar year. The log-rank test was used
to compare the different types of SpA and to compare the sur-
vival curves of SpA and RA. Cox regression models were used
to measure the differences in discontinuation rate between the
two diagnostic groups as well as to measure association
between risk factors and discontinuation. Besides estimation
of drug survival and retention rate, the incidence rates of AEs
were compared, and Cox regression analyses were used to
detect and adjust for independent factors other than the diag-
nostic group. All analyses were performed using the Stata 9.1
program (StataCorp LP, College Station, TX, USA).
Results
A majority of the patients registered in BIOBADASER were
diagnosed with RA (n = 4,006; 68.46%). SpA accounts for
26.04% (n = 1,524), AS 43% (n = 657), and PsA 37% (n =
570). The characteristics of patients are summarised in Table
1.
Compared with patients with RA, patients with SpA were
younger (p < 0.001) and more frequently male (p < 0.001).
Adalimumab was rarely used in SpA (15 treatments [0.90%]
versus 577 [12.72%] in RA; p < 0.001).
The total exposure to TNF antagonists was 2,430 patient-
years for SpA and 7,865 for RA. A detailed exposure rate by
biologic and diagnosis is shown in Table 2. As expected,
patients with RA not only had larger exposure in terms of
patient-years, but also had used different biologic treatments
more frequently. Adalimumab contributed little to the exposure
to biologics in our population.
Survival of TNF antagonists in SpA is significantly greater than
in RA at 1, 2, and 3 years (Table 3), and the difference seems
even larger with prolonged exposures (Figure 1). As shown in
Table 3 and Figure 1, there are no significant differences in
drug survival in the different types of SpA, although the group
of "other SpA," which includes reactive arthritis, juvenile SpA,
and chronic seronegative oligoarthritis, has lower drug survival
(yet due to the small size of the group did not reach statistical
significance [n = 42]).
The better survival in SpA is expressed by a hazard ratio (HR)
for discontinuation of 0.66 (95% confidence interval [CI],
0.58–0.76) compared with RA. There are unevenly distributed
factors in SpA and RA (Table 1) that had an impact on discon-
tinuation: being older than 60 (HR = 1.21 [95% CI, 1.08–
1.36]), being female (HR = 1.27 [95% CI, 1.13–1.43]), and
using infliximab (HR = 1.53 [95% CI, 1.31–1.78]). After
adjustment for these three factors, the HR for discontinuation
in SpA was 0.66 [95% CI, 0.57–0.76] compared with RA.
Survival of infliximab as first medication in SpA was signifi-
Table 2
Exposure to the different biologic response modifiers 
depending on diagnosis in BIOBADASER
Diagnosis Infliximab Etanercept Adalimumab
Rheumatoid arthritis 5,521 (840) 1,724 (188) 526 (67)
All spondylarthritis 1,915 (211) 507 (35) 5.7 (3)
Ankylosing 
spondylitis
873 (87) 134 (13) 0.8 (0)
Psoriatic arthritis 636 (84) 325 (16) 2.6 (2)
Undifferentiated 
spondylarthritis
257 (28) 35 (4) 1.4 (0)
Crohn's related 
spondylarthritis
124 (9) 2.8 (0) 0.7 (0)
Other 
spondylarthritis
22 (3) 9.5 (2) 0.3 (1)
Numbers indicate total patient-years. In parentheses are the numbers 
of treatments discontinued.Arthritis Research & Therapy    Vol 8 No 3    Carmona et al.
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cantly better than in RA (p = 0.0065). Similarly, survival of
etanercept as first medication in SpA was significantly better
than in RA (p = 0.0439). There were no differences however,
when survival of infliximab or etanercept as second medication
in RA was compared with their survival as second drug in SpA.
The distribution and the causes for discontinuation do not dif-
fer significantly in SpA and RA (pchi-square = 0.131). They are
AE (45.4% versus 48.7%), lack of efficacy (34.6% versus
36.0%), and others (19.9% versus 15.3%). The type of infec-
tion was also distributed equally in SpA and RA. Herpes zoster
virus and Mycobacterium tuberculosis were the leading iden-
tified microorganisms causing infection. Recommendations
for screening and treatment of latent tuberculosis were put in
place in March 2002 [35], and their impact has been reported
elsewhere [37].
The HR for discontinuation due to AEs does not differ signifi-
cantly among the types of SpA. On the contrary, the HR for
discontinuation due to lack of efficacy is statistically greater for
chronic seronegative arthritis than for the other types of SpA
(HR = 6.7 [95% CI, 1.6–28.2]). Compared with patients with
RA, patients with SpA treated with TNF antagonists have
fewer AEs (17% versus 26%, respectively, had one or more
AEs) that occur at a lower rate (13 events [95% CI, 11–14] in
SpA versus 17 events per 1,000 patient-years in RA [95% CI,
16–18]). The incidence risk ratioSpA versus RA is 0.78 [95% CI,
0.68–0.89]). The HR of presenting an AE in SpA compared
with RA is 0.69 [95% CI, 0.61–0.78]. However, as confirmed
by the confidence intervals in Table 4, there were no differ-
ences in the rate of any particular AE. For the purpose of this
study, discontinuation for AEs was considered when infusion
or injection treatment after the event was not received within
fourfold of the expected therapeutic interval. Under this defini-
tion, treatment was discontinued in 553 of 1,388 (39.8%) AEs
in RA and in 123 of 329 (37.4%) in SpA (p = 0.412). Further-
more, the proportion of AEs that ended in hospitalisation or a
prolonged hospital stay was 26.4% in RA and 21.3% in SpA
(p = 0.056). Rate of AEs associated with death was 3.9% in
RA and 1.5% in SpA (p = 0.034).
After adjustment for being older than 60 years (HR = 1.51
[95% CI, 1.37–1.67]), having a disease duration longer than
three years prior to therapy with TNF antagonist (HR = 1.29
[95% CI, 1.12–1.48]), and using infliximab (HR = 2.52 [95%
CI, 2.11–2.99]), the HR for an AE in SpA versus RA was 0.80
[95% CI, 0.70–0.91]. Adjustment for age as a continuous var-
iable did not produce different results than adjustment for age
as a dichotomized variable (older than 60 years).
Discussion
In the present study, we have analysed the survival of TNF
antagonists in patients with SpA in clinical practice in compar-
ison with RA patients in a registry. We have found that, due in
part to the occurrence of fewer AEs, patients with SpA have a
33% lower probability than patients with RA to discontinue
TNF antagonists.
Measuring effectiveness of drugs in registries such as BIOBA-
DASER is exposed to limitations. The voluntary medical regis-
tries need to be of high quality to be reliable [38]. The quality
of our database was ensured by repeated external audits of
the participating centres, as reported in Materials and meth-
ods. Following these quality assessment interventions, we
expect an error of approximately 11% in the information con-
sidered relevant to the analysis. This is within the 0%-17%
range reported by others [39].
Survival of a drug could be taken as an indication of drug effec-
tiveness in the clinical setting. Furthermore, studies with
extended follow-up and large numbers of patients are common
in rheumatology in assessing long-term effectiveness of treat-
Table 3
Drug survival at one, two, and three years by diagnosis
Drug survival [95% confidence interval]
Diagnosis One year Two years Three years
Rheumatoid arthritis 0.83 [0.81–0.84] 0.72 [0.71–0.74] 0.65 [0.63–0.67]
All spondylarthritis 0.88 [0.86–0.90]* 0.82 [0.79–0.84]* 0.74 [0.71–0.78]*
Ankylosing spondylitis 0.88 [0.85–0.91] 0.82 [0.78–0.86] 0.76 [0.70–0.80]
Psoriatic arthritis 0.88 [0.84–0.90] 0.81 [0.77–0.84] 0.73 [0.67–0.78]
Undifferentiated 
spondylarthritis
0.88 [0.81–0.91] 0.83 [0.76–0.88] 0.72 [0.60–0.80]
Crohn's related spondylarthritis 0.90 [0.79–0.95] 0.86 [0.73–0.93] 0.82 [0.69–0.91]
Other spondylarthritis 0.79 [0.53–0.92] 0.61 [0.31–0.81] 0.61 [0.31–0.81]
*p of the difference versus survival at the same time in rheumatoid arthritis < 0.001 (by log-rank test).Available online http://arthritis-research.com/content/8/3/R72
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ments [40]. However, these studies face limitations such as
confounding by indication, patient selection, and the absence
of a washout period [41].
Until recently, AS and PsA were difficult to evaluate in thera-
peutic trials because of the lack of standardised, widely
accepted, or validated instruments for assessing disease and
clinical response. This has changed in the past few years
[42,43]. Although the pathogeneses of SpA have not been
fully recognised, there appears to be a significant expression
of TNF in the entheses and peripheral joints in all the condi-
tions [44-47]. This has led to the use of TNF antagonists in the
treatment of SpA resistant to NSAIDs and the traditional
DMARDs. However, long-term studies in patients with SpA
treated with TNF antagonists are not yet available, and optimal
duration of therapy has not been established. In routine clinical
practice, physicians tend to treat patients with SpA over pro-
tracted periods (as in RA) and, as such, these insights from
our BIOBADASER database can provide valuable information
about physicians' prescribing patterns. Of note is the better
survival of TNF antagonists in patients with SpA than in
patients with RA.
A limitation of our study is that measures of joint inflammation
and damage were not collected, and therefore we can neither
adjust for baseline severity nor measure improvement in each
group. However, had we measured these parameters, it would
be difficult to compare activity in RA with activity in PsA. Sev-
eral parameters other than efficacy and safety (such as co-
morbidity, costs, availability of other therapies, patient and phy-
sician expectations, and medication compliance) have an
impact on the rate of discontinuation of a drug [48]. Absence
of alternative medications in the treatment of SpA may have
contributed to the favourable retention rate compared with RA.
Another explanation could be the lower rate of AEs in SpA.
This is explained, in part, by younger age and fewer co-medi-
cations in SpA than in RA, because age and co-medications
are associated with a greater number of AEs [49]. Neverthe-
less, the difference in risk of AEs cannot be fully explained by
these factors, because after the proper adjustments there is
still a 20% lower risk in SpA compared with RA. Adjustment
for potential confounders did not change the overall HR for
discontinuation of SpA. Because all confounders were more
likely to be present in RA, this suggests an interaction of one
of the variables and the type of disease. We cannot prove that
patients with SpA have fewer co-morbidities and use fewer
concomitant medications than do patients with RA, because
these data were collected only in patients who had AEs. How-
ever, comparison of both co-morbidities and concomitant
medication in SpA and in RA patients who had had an AE
reveals a significant difference (Mann-Whitney U  test, p  <
0.001). Also, RA itself could increase the rate of AEs in
patients treated with TNF antagonists. Interestingly, the higher
doses of infliximab recommended for SpA did not increase the
rate of AEs. Although the dose was not actually noted, the rec-
ommended dose is 5 mg/kg for SpA and 3 mg/kg for RA
(Summary of Product Characteristics of infliximab). Neither
was it recorded whether the interval between infusions was
shortened in patients not responding. This might have been
the case in the early phases, when only infliximab was availa-
ble, but was less probable thereafter.
Of note is that the HR of discontinuation of PsA versus RA
was 0.81 (95% CI, 0.66–0.99). After adjustment for age, it
Figure 1
Survival of tumor necrosis factor antagonists in patients with spondylarthritis (SpA) and rheumatoid arthritis Survival of tumor necrosis factor antagonists in patients with spondylarthritis (SpA) and rheumatoid arthritisA
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Table 4
Types of adverse events occurring in patients with spondylarthritis and rheumatoid arthritis treated with biologics
Spondylarthritis Rheumatoid arthritis
Biologic and total exposure Infliximab 1,915 Etanercept 507 Adalimumab 5.7 Infliximab 5,521 Etanercept 1,724 Adalimumab 526
Type of adverse event Cases IR [95% CI] Cases IR [95% CI] Cases IR [95% CI] Cases IR [95% CI] Cases IR [95% CI] Cases IR [95% CI]
Infusion reaction 72 4.14 [3.29–5.22] 1 0.20 [0.03–1.4] 0 - 252 5.09 [4.50–5.76] 7 0.43 [0.21–0.91] 6 1.36 [0.61–3.03]
Infection 102 5.87 [4.83–7.13] 5 1.01 [0.42–2.43] 1 18.90 [2.66–134.14] 350 7.07 [6.37–7.85] 28 1.74 [1.20–2.52] 56 12.71 [9.78–16.52]
Cutaneous 22 1.27 [0.83–1.92] 2 0.40 [0.10–1.61] 1 18.90 [2.66–134.14] 50 1.01 [0.77–1.33] 21 1.30 [0.85–2.00] 40 9.08 [6.66–12.38]
Cytopenia 2 0.12 [0.03–0.46] 0 - 0 - 27 0.54 [0.37–0.80] 3 0.19 [0.06–0.58] 3 0.68 [0.22–2.11]
Neoplastic 6 0.35 [0.16–0.77] 1 0.20 [0.03–1.4] 0 - 20 0.40 [0.26–0.63] 8 0.50 [0.25–0.99] 1 0.23 [0.03–1.61]
Pulmonary 4 0.23 [0.09–0.61] 0 - 0 - 21 0.42 [0.28–0.65] 4 0.25 [0.09–0.66] 3 0.68 [0.22–2.11]
Cardiovascular 13 0.75 [0.43–1.29] 3 0.61 [0.20–1.88] 0 - 64 1.29 [1.01–1.65] 8 0.50 [0.25–0.99] 13 2.95 [1.71–5.08]
Endocrine 1 0.06 [0.01–0.41] 0 - 0 - 5 0.10 [0.04–0.24] 0 - 0 -
Gastrointestinal 25 1.44 [0.97–2.13] 3 0.61 [0.20–1.88] 0 - 32 0.64 [0.46–0.91] 5 0.31 [0.13–0.75] 19 4.31 [2.75–6.76]
Ophthalmologic 4 0.23 [0.09–0.61] 0 - 0 - 2 0.04 [0.01–0.16] 3 0.19 [0.06–0.58] 2 0.45 [0.11–1.82]
Psychiatric 3 0.17 [0.06–0.54] 0 - 0 - 2 0.04 [0.01–0.16] 0 - 6 1.36 [0.61–3.03]
Neurological 5 0.29 [0.12–0.69] 1 0.20 [0.03–1.43] 0 - 15 0.30 [0.18–0.50] 1 0.06 [0.01–0.44] 8 1.82 [0.91–3.63]
Gynecological 0 - 0 - 0 - 3 0.06 [0.02–0.19] 0 - 1 0.23 [0.03–1.61]
Urological 4 0.23 [0.09–0.61] 0 - 0 - 4 0.08 [0.03–0.22] 1 0.06 [0.01–0.44] 3 0.68 [0.22–2.11]
Others 17 Not estimated 2 Not estimated 0 Not estimated 83 Not estimated 10 Not estimated 23 Not estimated
Data are presented as cases documented and as incidence rate (IR) and 95% confidence interval (CI) per 100 patient-years of exposure.Available online http://arthritis-research.com/content/8/3/R72
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lost its statistical significance. It may be that the symptoms of
patients with PsA who predominantly have small-joint periph-
eral disease (that is, who appear to have RA) behave more like
those of RA. This cannot be fully substantiated, because clini-
cal data to assess the type of PsA were not included in the
registry.
In patients with SpA, the rate of AEs with infliximab was
greater than with etanercept. This could merely reflect an over-
representation of patients treated with infliximab and with a
longer follow-up. Furthermore, a bias toward the use of a
"newer better" drug in the most severe cases or in non-
responder patients)[50] may have distorted the observed effi-
cacy; the availability of etanercept may have led to early dis-
continuation of infliximab, which had been cleared for use 40
months before etanercept. Head-to-head comparison will be
needed to answer this question.
Conclusion
Survival of TNF antagonists in SpA is better than in RA. At
present, TNF antagonists are an optimal, safe, and effective
therapeutic option for patients with severe SpA who fail to
respond to traditional drugs. Because chronic therapy is nec-
essary, continual review of this issue is necessary.
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